Amicus Therapeutics, Inc (FOLD) Dividend History

Company News

• New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

  Amicus Therapeutics announced the publication of a post-hoc analysis of data from the PROPEL study, which showed that patients with late-onset Pompe disease who switched from alglucosidase alfa to cipaglucosidase alfa-atga + miglustat experienced improvements or stability in most outcomes, while those who remained on alglucosidase alfa generally showed worsening or stability.

  GlobeNewswire Inc.
• Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

  Alnylam Pharmaceuticals has submitted a regulatory filing in the EU for its investigational drug vutrisiran to treat ATTR amyloidosis with cardiomyopathy. The filing is supported by positive results from a late-stage study, and if approved, the drug has the potential to become the new standard of care for ATTR-CM treatment.

  Benzinga

  Featured Companies: ALNY ANIP
• Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

  Amicus Therapeutics reported strong Q2 2024 results, with revenue up 34% year-over-year and EPS beating estimates. The company's key metrics, including geographic revenues and net product revenues, also showed solid performance.

  Zacks Investment Research
• Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?

  Investing.com

  Featured Companies: EXAS HOLX
• Trading The Top 10 Stocks From 40 Large Hedge Funds: Trading Update 9/4/2022

  A strategy selecting 10 of the 50 stocks, equally weighted, would have increased total return to 178.0%, an active return of 61.6% vs. SPY.

  Seeking Alpha

  Featured Companies: AAPL ADBE AMT AMZN APP BRK.A BRK.B BSX CHTR CNI CRM CRWD DHR DOCU ELV FATE FIS GFS GOOG GOOGL INCY INTU KMX MA MCO META MSFT MU NFLX NOW NVDA QCOM SCHW SNOW SPGI TDG TMO TMUS TSLA UBER UNH UNP V W WDAY